Safety and efficacy of Tivozanib in first-line mRCC: a multicenter compassionate use study (Meet-URO 16) - Meet-URO

Safety and efficacy of Tivozanib in first-line mRCC: a multicenter compassionate use study (Meet-URO 16)

Safety and efficacy of Tivozanib in first-line mRCC: a multicenter compassionate use study (Meet-URO 16)

Autore

Umberto Basso

Patologia

Rene

Rivista

Oncology

Anno

2021

DOI

https://doi.org/10.1159/000515951

Studio di riferimento